About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price ...

Supernus Pharmaceuticals (NASDAQ ... which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st ...

4. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. 5. These restricted stock units are settled in common stock upon vesting, which ...

Supernus Pharmaceuticals CEO will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2025. Supernus Pharmaceuticals, Inc., a biopharmaceutical company specializing ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

TL;DR: SK hynix has achieved a 70% yield rate on its HBM4 12-Hi memory, which is set to be used in NVIDIA's upcoming Rubin R100 AI GPUs. SK hynix has reportedly reached a 70% yield rate on its ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) yesterday and set a price target of $36.00. The company’s shares closed ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $36.00. The company’s shares closed yesterday ...